Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cicaderma for Preventing Radiodermatitis in Breast Cancer
NCT04300829Phase 3Unknown
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cicaderma in radiation dermatitis (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Incidence of Grade >= 2 Radiodermatitis. Status: unknown.
02
Drugs
Cicaderma
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT04300829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300829.